Biogen (BIIB) is up after a notable analyst action: Wells Fargo upgraded the stock to Buy on April 20, 2026 and raised its price target to $250 from $200. The upgrade is acting as the primary near-term catalyst, signaling increasing confidence that Biogen’s next wave of products and pipeline milestones can offset ongoing erosion in its legacy multiple-sclerosis franchise. (investing.com)

The bullish reset centers on pipeline momentum and a catalyst calendar that becomes more active through 2026, which has been a recurring theme among bullish analysts following Biogen’s strategic pivot. Investors are treating the upgrade as confirmation that the valuation now better reflects near-term earnings pressure while underpricing potential upside from later-stage assets and lifecycle management opportunities. (investing.com)

Biogen’s most recent guidance has framed 2026 as a transition year, with management emphasizing cost discipline and continued investment in the pipeline. A major near-term milestone referenced in company materials is the FDA action date of April 3, 2026 for a high-dose regimen of SPINRAZA (nusinersen) in spinal muscular atrophy, which investors have viewed as a meaningful franchise-supporting event. (investors.biogen.com)

Near-term follow-through will likely depend on whether additional analysts echo the more bullish stance and whether upcoming regulatory/clinical events reinforce the idea that Biogen’s growth products can stabilize the base business. Traders will also be watching for any updated commentary from the company around 2026 execution and timing of key readouts, as sentiment remains sensitive to both pipeline news and trajectory in the legacy MS portfolio.